Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin Bo

Showing results (841-850 of 851) with videos related to

Pageof 86
Sort By:
The Lancet Regional Health. Western Pacific|September 8, 2025
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trialGuo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
The Lancet. Infectious Diseases|July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trialFeng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Nature Communications|March 6, 2021
Cytotoxic CD8<sup>+</sup> T cells promote granzyme B-dependent adverse post-ischemic cardiac remodelingIcia Santos-Zas, Jeremie Lemarié, Ivana Zlatanova, et al.
The Lancet. Infectious Diseases|April 13, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trialHong-Xing Pan, Ling-Xian Qiu, Qi Liang, et al.
Journal of Global Antimicrobial Resistance|July 17, 2025
Emerging epidemic of the predominant clusters of FC428-like Neisseria gonorrhoeae in Guangdong, ChinaYang Chen, Xiao-Lin Qin, Han Zhou, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Military Medical Research|June 19, 2026
Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort studyYun-Bo He, Jiao Hu, Zhi Liu, et al.
Nature Plants|January 31, 2018
A genome for gnetophytes and early evolution of seed plantsTao Wan, Zhi-Ming Liu, Ling-Fei Li, et al.
Pageof 86

Showing results (841-850 of 851) with videos related to

Sort By:
Pageof 86
The Lancet Regional Health. Western Pacific|September 8, 2025
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trialGuo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
The Lancet. Infectious Diseases|July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trialFeng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Nature Communications|March 6, 2021
Cytotoxic CD8<sup>+</sup> T cells promote granzyme B-dependent adverse post-ischemic cardiac remodelingIcia Santos-Zas, Jeremie Lemarié, Ivana Zlatanova, et al.
The Lancet. Infectious Diseases|April 13, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trialHong-Xing Pan, Ling-Xian Qiu, Qi Liang, et al.
Journal of Global Antimicrobial Resistance|July 17, 2025
Emerging epidemic of the predominant clusters of FC428-like Neisseria gonorrhoeae in Guangdong, ChinaYang Chen, Xiao-Lin Qin, Han Zhou, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Military Medical Research|June 19, 2026
Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort studyYun-Bo He, Jiao Hu, Zhi Liu, et al.
Nature Plants|January 31, 2018
A genome for gnetophytes and early evolution of seed plantsTao Wan, Zhi-Ming Liu, Ling-Fei Li, et al.
Pageof 86